← Back to all trials
Completed
NCT03395522
Study to Assess the Efficacy of the iTind in Subjects With Symptomatic BPH
Conditions: BPH
Sex: Male
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 149
Sponsor: Medi-Tate Ltd.
Location: Sydney Adventist Hospital Clinical School of the University of Sydney Sydney
Summary
A total of up to 200 Symptomatic BPH subjects subjects will be enrolled into the study.
Study duration will be 12 months post implantation with a follow-up visits at Year 2 and Year 3.
Eligibility Criteria
Inclusion Criteria:
Subject signed informed consent prior to the performance of any study procedures.
* Male with symptomatic BPH: IPSS symptom severity score ≥ 10
* Peak urinary flow of \< 12 ml/sec at flowmetry with minimum voided volume of at least 120 cc.
* Prostate volume 25 ml to 80 ml (as assessed by TRUS)
* Subject that is able to complete the study protocol
* Normal Urinalysis and urine culture.
Exclusion Criteria:
* Previous prostate surgery
* Prostate cancer
* Urethral stricture
* Bladder stones
* An active urinary tract infection.
* Obstructing median lobe demonstrated by IPP grade 3 (\>1 cm) as assessed by TRUS.
* Neurological conditions potentially affecting voiding function.
* A post void residual (PVR) volume \> 250 ml measured by ultrasound
* Previous diagnosis or treatment for Over Active Bladder
* Acute Urinary Retention
* Any anatomical or physiological condition that in the opinion of the investigator likely to impede successful completion of the study
Intra-Operation Exclusion:
• Obstructing median lobe or any other anatomical or physiological pathology that can interfere the device implantation as assessed by cystoscopy.
Source: ClinicalTrials.gov (NCT03395522). StuddyBuddy aggregates publicly available trial information.